慢性缩性胃炎的生物标志物识别及其潜在药物分析
Biao Song1, Qinglin Cao1, Tingting Li2
1The Graduated School, Anhui University of Traditional Chinese Medicine, Hefei, China.
Frontiers in gastroenterology (Lausanne, Switzerland)
|March 13, 2026
概括
生物信息学分析确定ATP4A,CFTR和EPCAM是慢性缩性胃炎 (CAG) 的潜在生物标志物. 这项研究还揭示了CAG的新型治疗药物,为胃癌的预防和治疗提供了新的途径.
科学领域:
- 基因组学和生物信息学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 慢性缩性胃炎 (CAG) 是胃癌 (GC) 的前体.
- 了解CAG的致病性对于GC的预防和治疗至关重要.
- 本研究使用生物信息学来确定CAG的生物标志物和治疗点.
研究的目的:
- 使用生物信息学探索CAG的潜在生物标志物.
- 确定用于CAG治疗的新型治疗药物.
- 阐明CAG进展背后的分子机制.
主要方法:
- 从基因表达综合 (GEO) 数据库下载并分析了GSE11632数据集.
- 鉴定了差异表达基因 (DEGs),并将它们与来自GeneCard和DisGeNET的CAG相关基因交叉.
- 利用生物信息学工具,包括GEO2R,Cytoscape和连接地图 (CMap) 来进行基因表达,网络和药物分析.
主要成果:
- 确定了42个与CAG相关的差异表达基因 (DEG),其中24个是胃特异的.
- 发现了6个关键的枢纽基因,其中ATP4A,CFTR和EPCAM具有高诊断价值.
- 预测了13种潜在的调节性miRNA,并确定了对CAG的五种潜在治疗药物.
结论:
- ATP4A,CFTR和EPCAM是CAG的潜在诊断生物标志物.
- 特定的miRNA-CFTR相互作用 (hsa-miR-185-5p,hsa-miR-4644,hsa-miR-4505) 可能调节CAG的进展.
- 阿莫纳菲德,埃托波西德,甲酸-莫菲蒂尔,环胺和埃梅丁作为CAG的治疗剂显示出希望.
相关概念视频
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
742
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
742
01:30Serum Laboratory Studies, Stool Test, Breath Test
1.0K
Gastrointestinal (GI) diagnostic studies are pivotal in confirming, ruling out, diagnosing, or staging various diseases, including cancers. Following diagnosis, allocating time for discussions with the patient and providing informational resources is crucial. Diagnostic assessments of the GI tract often occur in outpatient settings like endoscopy suites or GI labs. Preparation for these tests may include dietary restrictions, fasting, liquid bowel preparations, laxatives, enemas, and the...
1.0K
01:23Gastritis III: Clinical Manifestations and Management
1.6K
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.6K
01:27Gastritis-I: Introduction and Types
3.0K
Gastritis, defined by the inflammation or irritation of the stomach lining or gastric mucosa, manifests in several distinct forms: acute, chronic, reactive, and a specific subtype known as autoimmune metaplastic atrophic gastritis.
Acute gastritis presents as a sudden inflammation triggered by various stressors to the stomach lining, such as exposure to corrosive agents, local irritants like aspirin and other NSAIDs, alcohol consumption, radiation therapy, physical trauma, severe burns, sepsis,...
Acute gastritis presents as a sudden inflammation triggered by various stressors to the stomach lining, such as exposure to corrosive agents, local irritants like aspirin and other NSAIDs, alcohol consumption, radiation therapy, physical trauma, severe burns, sepsis,...
3.0K
01:29Pharmacogenomics: Identification of New Drug Targets
61
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
61
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
247
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
247